Suggested Citation: "7 Moving Ahead." National Academies of Sciences, Engineering, and Medicine. 2019. Forest Health and Biotechnology: Possibilities and ...

The Potential for Biotechnology to Address Forest Health will focus on trees and consider the use of biotechnology to prevent the extirpation of a single tree species by an insect or disease that ...

Physiology explains how living systems function and remains the foundation of modern medicine. In this episode of The Top Line, Sue Bodine, president-elect of the American Physiological Society and a ...

The interest and need are here. The authors acknowledge that cloud-based and AI-driven technologies are increasingly automating drug discovery and advancing biomedical research. The global AI market ...

As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Trinity Biotech launched CGM+, an AI-native wearable biosensor for glucose and multi-data monitoring, targeting the expanding healthcare market. Trinity Biotech plc, a biotechnology company ...

The news hit the biotech industry like a bucket of cold water: the White House's proposed plan to significantly cut funding from the National Institutes of Health (NIH). As the primary U.S. agency ...

Market breadth remains fragile as equal-weighted indexes lag, pointing to thin liquidity and uneven sector rotation.Health care and biotech are emerging as relative winners, with XBI showing technical ...

The MarketWatch News Department was not involved in the creation of this content. BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GATC Health, a leading tech-bio company leveraging artificial intelligence ...

AI search is fundamentally changing how consumers navigate decision making, and brands must adapt in order to be discoverable.

Fortress Biotech, Inc. (NASDAQ:FBIO) said its majority-owned subsidiary Cyprium Therapeutics has signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for gross ...